Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBIO6E)

• Drug Name: Meclinertant Drug Info
• Synonyms: Reminertant; SR 48692; SR48692; SR-48692; 2-(((1-(7-Chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl)carbonyl)amino)tricyclo(3.3.1.1(sup 3,7))decane-2-carboxylic acid; 2-((1-(7-Chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)pyrazol-3-yl)carbonylamino)tricyclo(3.3.1.1.(3.7))decan-2-carboxylic acid;2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Inflammatory bowel disease	DD72	Phase 2/3	[1]

• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 119192
  ChEBI ID: CHEBI:125516
  CAS Number: CAS 146362-70-1
  TTD Drug ID: DMBIO6E

Molecule-Related Drug Atlas

Drug(s) Targeting Neurotensin receptor type 1 (NTSR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ABS-212	DMZ52P6	Pain	MG30-MG3Z	Terminated	[3]
CGX-1160	DMADYF7	Acute or chronic pain	MG30-MG31	Terminated	[4]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	DMM9X0G	Discovery agent	N.A.	Investigative	[5]
JMV458	DMC1ARG	Discovery agent	N.A.	Investigative	[6]
Neurotensin(8-13)	DMOBU62	N. A.	N. A.	Investigative	[7]
JMV449	DME9GF8	Discovery agent	N.A.	Investigative	[8]
SR48527	DMUHQS9	Discovery agent	N.A.	Investigative	[9]
HBN-2	DM5VDU2	Neurological disorder	6B60	Investigative	[10]
[3H]meclinertant	DMEX6GT	Discovery agent	N.A.	Investigative	[9]
H-Arg-Arg-Pro-Tyr-Ile-Aac-OH	DMENVKA	Discovery agent	N.A.	Investigative	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Neurotensin receptor type 1 (NTSR1)	TTTUMEP	NTR1_HUMAN	Antagonist	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1582).
• [2] Neurotensin inversely modulates maternal aggression. Neuroscience. 2009 Feb 18;158(4):1215-23.
• [3] Identification and functional characterization of a stable, centrally active derivative of the neurotensin (8-13) fragment as a potential first-in-class analgesic. J Med Chem. 2010 Jun 24;53(12):4623-32.
• [4] Clinical status of anti-cancer agents derived from marine sources. Anticancer Agents Med Chem. 2008 Aug;8(6):603-17.
• [5] Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
• [6] Agonism, inverse agonism, and neutral antagonism at the constitutively active human neurotensin receptor 2. Mol Pharmacol. 2001 Dec;60(6):1392-8.
• [7] Comparison of N-terminal modifications on neurotensin(8-13) analogues correlates peptide stability but not binding affinity with in vivo efficacy. J Med Chem. 2009 Apr 9;52(7):1803-13.
• [8] Differential involvement of intracellular domains of the rat NTS1 neurotensin receptor in coupling to G proteins: a molecular basis for agonist-directed trafficking of receptor stimulus. Mol Pharmacol. 2003 Aug;64(2):421-9.
• [9] [3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor. Mol Pharmacol. 1995 May;47(5):1050-6.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 309).
• [11] Novel insights into GPCR-peptide interactions: mutations in extracellular loop 1, ligand backbone methylations and molecular modeling of neurotensi... Bioorg Med Chem. 2008 Oct 15;16(20):9359-68.